Shawn Lee
Vice President Orum Therapeutics
• Obtain Ph.D. from the University of Texas at Dallas
• Postdoctoral training at Dr. Thomas Roberts’ lab at Dana-Farber Cancer Insititue
• A cancer biologist and drug discovery scientist with extensive experience with various modalities, including small molecule inhibitors, PROTACs, and DACs
Seminars
Wednesday 10th June 2026
Bridging Two Modalities: Explore How Dual-Precision Targeted Protein Degradation (TPD2) Enables Cell-Specific GSPT1 Degradation for Potent Antitumor Activity
6:30 pm
- Discover how Orum’s TPD² platform fuses antibody targeting with catalytic protein degradation to deliver potent activity against undruggable intracellular targets
- Discuss ORM-1153, a CD123-targeting Degrader Antibody Conjugate (DAC) with a novel GSPT1-degrading payload, with the aim of achieving selective delivery to AML blasts and inducing cytotoxicity via GSPT1 degradation
- Outline the proprietary linker technology used to enable the stable conjugation and subsequent traceless, intracellular release of the TPD payloads from the antibody
